Symbols / REVB Stock $1.05 +7.14% Revelation Biosciences, Inc.

Healthcare • Biotechnology • United States • NCM
REVB (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. James M. Rolke
Exch · Country NCM · United States
Market Cap 4.10M
Enterprise Value -9.25M
Income -21.50M
Sales —
FCF (ttm) -5.16M
Book/sh 3.32
Cash/sh 3.61
Employees 8
Insider 10d —
IPO Nov 17, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.38
PEG —
P/S —
P/B 0.32
P/C —
EV/EBITDA 0.92
EV/Sales —
Quick Ratio 9.96
Current Ratio 10.02
Debt/Eq 5.84
LT Debt/Eq —
EPS (ttm) -1.32
EPS next Y -2.77
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-07
Earnings (prior) 2026-05-07
ROA -66.19%
ROE -124.41%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 3.91M
Shs Float 3.44M
Insider Own 4.79%
Instit Own 12.78%
Short Float 0.70%
Short Ratio 0.45
Short Interest 26.24K
52W High 12.88
vs 52W High -91.85%
52W Low 0.88
vs 52W Low 20.00%
Beta -0.10
Impl. Vol. —
Rel Volume 0.75
Avg Volume 68.94K
Volume 51.96K
Target (mean) $19.25
Tgt Median $19.25
Tgt Low $16.00
Tgt High $22.50
# Analysts 2
Recom None
Prev Close $0.98
Price $1.05
Change 7.14%
About

Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company's lead product candidate is lead product candidate Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response. It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease. The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$19.25
Mean price target
2. Current target
$1.05
Latest analyst target
3. DCF / Fair value
$-23.75
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.05
Low
$16.00
High
$22.50
Mean
$19.25
News
RSS: Latest REVB news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-01-08 CHAWLA LAKHMIR S Director — 41,981 $0.90 $37,783
2026-01-08 CARVER JENNIFER A Director — 41,981 $0.90 $37,783
2026-01-08 ROLKE JAMES M Chief Executive Officer — 532,829 $0.90 $479,546
2026-01-08 ZYGMONT CHESTER STANLEY III Chief Financial Officer — 78,145 $0.90 $70,330
2026-01-08 ROPER JESS Director — 41,981 $0.90 $37,783
2025-10-29 CHAWLA LAKHMIR S Director — 15,625 $1.28 $20,000
2025-10-29 CARVER JENNIFER A Director — 15,625 $1.28 $20,000
2025-10-29 ROLKE JAMES M Chief Executive Officer — 390,614 $1.28 $499,986
2025-10-29 ZYGMONT CHESTER STANLEY III Chief Financial Officer — 390,614 $1.28 $499,986
2025-10-29 ROPER JESS Director — 15,625 $1.28 $20,000
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
9.07
+13.74%
7.98
-7.87%
8.66
-20.32%
10.86
Research And Development
4.06
+14.51%
3.55
-14.40%
4.15
-22.90%
5.38
Selling General And Administration
5.01
+13.12%
4.43
-1.88%
4.51
-17.79%
5.49
General And Administrative Expense
5.01
+13.12%
4.43
-1.88%
4.51
-17.79%
5.49
Salaries And Wages
3.05
+10.02%
2.77
+21.86%
2.27
+21.19%
1.87
Other Gand A
1.96
+18.31%
1.66
-25.96%
2.24
-38.03%
3.61
Total Expenses
9.07
+13.74%
7.98
-7.87%
8.66
-20.32%
10.86
Operating Income
-9.07
-13.74%
-7.98
+7.87%
-8.66
+20.32%
-10.86
Total Operating Income As Reported
-9.07
-13.74%
-7.98
+7.87%
-8.66
+20.32%
-10.86
EBITDA
-9.04
-13.80%
-7.95
+7.93%
-8.63
+20.37%
-10.84
Normalized EBITDA
-9.05
-12.67%
-8.03
+52.66%
-16.96
-56.47%
-10.84
Reconciled Depreciation
0.03
-3.10%
0.03
+11.47%
0.03
+0.00%
0.03
EBIT
-9.07
-13.74%
-7.98
+7.87%
-8.66
+20.32%
-10.86
Total Unusual Items
0.00
-97.35%
0.08
-99.02%
8.33
—
Total Unusual Items Excluding Goodwill
0.00
-97.35%
0.08
-99.02%
8.33
—
Net Income
-8.91
+40.73%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Pretax Income
-8.91
+40.73%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Other Income Expense
0.16
+102.23%
-7.06
-182.74%
8.54
+24316.25%
0.03
Other Non Operating Income Expenses
0.16
+102.17%
-7.14
-3543.76%
0.21
+493.42%
0.03
Gain On Sale Of Security
0.00
-97.35%
0.08
-99.02%
8.33
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-8.91
+40.73%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Net Income From Continuing Operation Net Minority Interest
-8.91
+40.73%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Net Income From Continuing And Discontinued Operation
-8.91
+40.73%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Net Income Continuous Operations
-8.91
+40.73%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Normalized Income
-8.92
+41.03%
-15.12
-78.95%
-8.45
+21.98%
-10.83
Net Income Common Stockholders
-14.87
+1.15%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Otherunder Preferred Stock Dividend
5.95
0.00
—
—
Diluted EPS
-23.95
+97.72%
-1,052.16
-938.86%
-101.28
+99.89%
-91,775.84
Basic EPS
-23.95
+97.72%
-1,052.16
-938.86%
-101.28
+99.89%
-91,775.84
Basic Average Shares
0.62
+4243.58%
0.01
+1104.04%
0.00
+905.93%
0.00
Diluted Average Shares
0.62
+4243.58%
0.01
+1104.04%
0.00
+905.93%
0.00
Diluted NI Availto Com Stockholders
-14.87
+1.15%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
11.58
+74.91%
6.62
-45.78%
12.21
+121.91%
5.50
Current Assets
10.81
+64.67%
6.57
-45.95%
12.15
+124.40%
5.41
Cash Cash Equivalents And Short Term Investments
10.70
+64.65%
6.50
-45.80%
11.99
+128.28%
5.25
Cash And Cash Equivalents
10.70
+64.65%
6.50
-45.80%
11.99
+128.28%
5.25
Prepaid Assets
0.08
+349.76%
0.02
-68.85%
0.06
0.00
Current Deferred Assets
—
0.00
-100.00%
0.07
-18.40%
0.09
Other Current Assets
0.03
-31.42%
0.05
+67.94%
0.03
-59.69%
0.07
Total Non Current Assets
0.77
+1269.20%
0.06
-13.45%
0.07
-27.79%
0.09
Net PPE
0.74
+1214.27%
0.06
-13.45%
0.07
-27.79%
0.09
Gross PPE
0.84
+455.36%
0.15
+14.53%
0.13
+0.00%
0.13
Accumulated Depreciation
-0.10
-4.42%
-0.09
-41.75%
-0.07
-59.88%
-0.04
Other Properties
0.84
+455.36%
0.15
+14.53%
0.13
+0.00%
0.13
Other Non Current Assets
0.03
—
—
—
Total Liabilities Net Minority Interest
2.72
+42.24%
1.91
-65.61%
5.56
+25.03%
4.45
Current Liabilities
2.00
+4.42%
1.91
-65.61%
5.56
+25.03%
4.45
Payables And Accrued Expenses
1.98
+3.21%
1.91
-23.83%
2.51
+63.17%
1.54
Payables
0.58
-26.30%
0.78
-42.38%
1.36
+145.38%
0.55
Accounts Payable
0.58
-26.30%
0.78
-42.38%
1.36
+145.38%
0.55
Current Accrued Expenses
1.40
+23.68%
1.13
-1.94%
1.15
+16.94%
0.99
Current Debt And Capital Lease Obligation
0.02
—
—
—
Current Capital Lease Obligation
0.02
0.00
—
0.00
Current Deferred Liabilities
—
0.00
-100.00%
2.91
+0.00%
2.91
Other Current Liabilities
—
0.00
-98.41%
0.14
—
Total Non Current Liabilities Net Minority Interest
0.72
0.00
0.00
0.00
Long Term Debt And Capital Lease Obligation
0.72
0.00
—
—
Long Term Capital Lease Obligation
0.72
0.00
—
—
Stockholders Equity
8.86
+88.20%
4.71
-29.17%
6.65
+531.64%
1.05
Common Stock Equity
8.86
+88.20%
4.71
-29.17%
6.65
+531.64%
1.05
Capital Stock
0.00
+3500.00%
0.00
+175.00%
0.00
-79.22%
0.00
Common Stock
0.00
+3500.00%
0.00
+175.00%
0.00
-79.22%
0.00
Preferred Stock
—
0.00
0.00
0.00
Share Issued
1.58
+3539.80%
0.04
+3060.35%
0.00
+1066.95%
0.00
Ordinary Shares Number
1.58
+3539.80%
0.04
+3060.35%
0.00
+1066.95%
0.00
Additional Paid In Capital
58.28
+28.90%
45.21
+40.79%
32.11
+21.65%
26.40
Retained Earnings
-49.42
-22.01%
-40.51
-59.05%
-25.47
-0.47%
-25.35
Total Equity Gross Minority Interest
8.86
+88.20%
4.71
-29.17%
6.65
+531.64%
1.05
Total Capitalization
8.86
+88.20%
4.71
-29.17%
6.65
+531.64%
1.05
Working Capital
8.81
+89.45%
4.65
-29.33%
6.58
+584.04%
0.96
Invested Capital
8.86
+88.20%
4.71
-29.17%
6.65
+531.64%
1.05
Total Debt
0.75
0.00
—
0.00
Capital Lease Obligations
0.75
0.00
—
0.00
Net Tangible Assets
8.86
+88.20%
4.71
-29.17%
6.65
+531.64%
1.05
Tangible Book Value
8.86
+88.20%
4.71
-29.17%
6.65
+531.64%
1.05
Preferred Stock Equity
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-8.27
+54.86%
-18.32
-151.45%
-7.29
+35.06%
-11.22
Cash Flow From Continuing Operating Activities
-8.27
+54.86%
-18.32
-151.45%
-7.29
+35.06%
-11.22
Net Income From Continuing Operations
-8.91
+40.73%
-15.04
-12405.64%
-0.12
+98.89%
-10.83
Depreciation Amortization Depletion
0.03
-3.10%
0.03
+11.47%
0.03
+0.00%
0.03
Depreciation
0.03
-3.10%
0.03
+11.47%
0.03
+0.00%
0.03
Depreciation And Amortization
0.03
-3.10%
0.03
+11.47%
0.03
+0.00%
0.03
Other Non Cash Items
0.02
-25.48%
0.03
—
0.01
Stock Based Compensation
0.60
+252.60%
0.17
+8.43%
0.16
-48.29%
0.30
Operating Gains Losses
0.01
+111.11%
-0.08
+99.02%
-8.33
—
Gain Loss On Investment Securities
-0.00
+97.35%
-0.08
+99.02%
-8.33
—
Gain Loss On Sale Of PPE
0.01
0.00
—
—
Change In Working Capital
-0.01
+99.82%
-3.42
-448.53%
0.98
+234.36%
-0.73
Change In Prepaid Assets
-0.04
-347.88%
0.02
+255.65%
-0.01
-102.03%
0.57
Change In Payables And Accrued Expense
0.06
+101.81%
-3.51
-485.27%
0.91
+174.59%
-1.22
Change In Accrued Expense
0.27
+109.19%
-2.94
-1912.71%
0.16
+129.13%
-0.56
Change In Payable
-0.21
+64.23%
-0.58
-176.87%
0.75
+212.55%
-0.67
Change In Account Payable
-0.21
+64.23%
-0.58
-176.87%
0.75
+212.55%
-0.67
Change In Other Working Capital
—
0.07
-13.33%
0.08
+234.20%
-0.06
Change In Other Current Assets
-0.03
0.00
—
—
Change In Other Current Liabilities
0.01
0.00
0.00
+100.00%
-0.02
Investing Cash Flow
0.00
+100.00%
-0.02
0.00
0.00
Cash Flow From Continuing Investing Activities
0.00
+100.00%
-0.02
0.00
0.00
Net PPE Purchase And Sale
0.00
+100.00%
-0.02
0.00
0.00
Purchase Of PPE
0.00
+100.00%
-0.02
0.00
0.00
Capital Expenditure
—
-0.02
—
—
Financing Cash Flow
12.47
-2.93%
12.85
-8.39%
14.03
-7.72%
15.20
Cash Flow From Continuing Financing Activities
12.47
-2.93%
12.85
-8.39%
14.03
-7.72%
15.20
Net Issuance Payments Of Debt
—
—
0.00
+100.00%
-0.80
Issuance Of Debt
—
—
0.00
-100.00%
2.50
Repayment Of Debt
—
—
0.00
+100.00%
-3.30
Short Term Debt Issuance
—
—
0.00
-100.00%
2.50
Short Term Debt Payments
—
—
0.00
+100.00%
-3.30
Net Short Term Debt Issuance
—
—
0.00
+100.00%
-0.80
Net Common Stock Issuance
3.39
-37.45%
5.42
-61.39%
14.03
+215.21%
4.45
Repurchase Of Capital Stock
—
0.00
+100.00%
-0.01
—
Proceeds From Stock Option Exercised
9.08
+22.23%
7.43
+21854932.35%
0.00
-99.33%
0.01
Net Other Financing Charges
—
—
—
11.53
Changes In Cash
4.20
+176.49%
-5.49
-181.51%
6.74
+69.39%
3.98
Beginning Cash Position
6.50
-45.80%
11.99
+128.28%
5.25
+312.09%
1.27
End Cash Position
10.70
+64.65%
6.50
-45.80%
11.99
+128.28%
5.25
Free Cash Flow
-8.27
+54.91%
-18.34
-151.71%
-7.29
+35.06%
-11.22
Change In Interest Payable
—
—
0.00
-100.00%
0.04
Common Stock Issuance
3.39
-37.45%
5.42
-61.39%
14.03
+215.21%
4.45
Issuance Of Capital Stock
3.39
-37.45%
5.42
-61.39%
14.03
+214.85%
4.46
Net Preferred Stock Issuance
—
0.00
+100.00%
-0.01
-200.00%
0.01
Preferred Stock Issuance
—
—
—
0.01
Preferred Stock Payments
—
0.00
+100.00%
-0.01
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category